Randomised clinical trial: the DPP‐4 inhibitor, vildagliptin, inhibits gastric accommodation and increases glucagon‐like peptide‐1 plasma levels in healthy volunteers KU Leuven
Background: Dipeptidyl peptidase‐4 (DPP‐4) inactivates glucagon‐like peptide‐1 (GLP‐1). Whether DPP‐4 inhibition affects GLP‐1 metabolism and/or food intake in humans remains unknown. Aims: To evaluate the effect of vildagliptin (DPP‐4 inhibitor) on gastric accommodation and ad libitum food intake in healthy volunteers (HVs) Methods: The effects of acute oral vildagliptin administration (50 mg) were evaluated in two randomised, ...